Aprea Therapeutics Inc. Common stock (APRE)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look first for a durable business earning cash. Aprea is not that. It is a clinical-stage biopharma with eight employees, no reported revenue in the filed periods, and net losses in fiscal Q2 2026, the quarter ended 2026-06-30 (-$3.6M); fiscal Q1 2026, the quarter ended 2026-03-31 (-$3.3M); fiscal Q3 2025, the quarter ended 2025-09-30 (-$3.0M); and fiscal Q2 2025, the quarter ended 2025-06-30 (-$3.2M). Full-year losses were $12.6M in FY2025, $13.0M in FY2024, and $14.3M in FY2023. That is a long runway of red ink. The FairStock calculations at the 2026-10-13 close show a market cap of only $7.6M, a negative P/E of -0.63, P/B of 0.19, ROE -46.15%, ROCE -27.73%, and trailing free cash flow of -$12.2M, for an FCF yield of -161.3%. The Piotroski F-Score of 1/9 and Altman Z-Score of -8.98 suggest extreme financial fragility. The Lynch category is none because it lost money in each of the last four years. A low price-to-book may hint at asset value, but without revenue and with cash burn exceeding the market cap, book value can vanish. The moat is unproven: two early-stage candidates, APR-1051 and ATRN-119, face years of trials and regulatory risk. Growth is not measurable from filed revenue. This is a lottery ticket on science, not a compounding business. Graham might call it speculative; Buffett would demand a margin of safety that only exists if cash and data justify it. I would watch cash runway, trial readouts, and financing dilution.

In plain English: Aprea Therapeutics is a tiny clinical-stage cancer drug company. It has no reported revenue and has been losing money for years while it tests experimental treatments. The stock price looks very low compared with its accounting value, but the business is not yet profitable and burns cash, so it is highly speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer